




**Pharmaceutical Congress:
Responding to the
Guidance**

Spring 2003

OIG Pharma Guidance

- **Panel Members**




Implications of the **OIG** Guidance



- **Key Improvements**
- **Biggest Challenges**


OIG Pharma Guidance

- **Will it prompt reassessment of written Standards of Conduct?**




OIG Pharma Guidance

- **Effects on Compliance Training?**



OIG Pharma Guidance


- **Pharmacy Benefit Managers**
- **What changes to Companies compliance programs?**



OIG Pharma Guidance



- **Drug Samples**
- **Changes to the processes relating to the monitoring or tracking of samples?**



OIG Pharma Guidance



- **Data Integrity**
- **How will compliance programs evolve to address the OIG's concerns?**



OIG Pharma Guidance

- **Role of Compliance Officers**
- **Any Changes?**



OIG Pharma Guidance

- Audience Questions?

